Hikari Tsushin Inc. Trims Stock Position in Danaher Corporation (NYSE:DHR)

Key Points

• Hikari Tsushin Inc. reduced its stake in Danaher Corporation by 2.3%, now holding 64,712 shares valued at approximately $13.27 million, making it the company's 15th largest position.
• Several hedge funds made significant changes to their positions in Danaher, with Nuveen LLC acquiring a new stake valued at around $833.94 million in the first quarter.
• Danaher’s recent earnings report surpassed expectations, with an EPS of $1.80 against a consensus estimate of $1.64, and revenues for the quarter reached $5.94 billion.

Hikari Tsushin Inc. lowered its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 2.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 64,712 shares of the conglomerate's stock after selling 1,557 shares during the quarter. Danaher makes up approximately 0.9% of Hikari Tsushin Inc.'s holdings, making the stock its 15th biggest position. Hikari Tsushin Inc.'s holdings in Danaher were worth $13,266,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. Nuveen LLC purchased a new position in shares of Danaher during the 1st quarter valued at about $833,941,000. GAMMA Investing LLC lifted its position in shares of Danaher by 24,958.2% during the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after buying an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after buying an additional 1,601,800 shares in the last quarter. Capital World Investors lifted its position in shares of Danaher by 32.7% during the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after buying an additional 1,566,658 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of analyst reports. Robert W. Baird lifted their price objective on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Jefferies Financial Group decreased their target price on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research note on Tuesday, April 22nd. Leerink Partners lifted their target price on Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a research note on Wednesday, April 23rd. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Finally, Argus decreased their target price on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Price Performance

Shares of DHR stock opened at $205.79 on Wednesday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The stock has a market capitalization of $147.36 billion, a price-to-earnings ratio of 43.79, a P/E/G ratio of 2.79 and a beta of 0.73. The stock has a fifty day simple moving average of $198.95 and a two-hundred day simple moving average of $200.34. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the business earned $1.72 EPS. The business's revenue for the quarter was up 3.4% compared to the same quarter last year. On average, analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.